Category: Thoratec Corp.
Shares of Thoratec Corp. slide after the New England Journal of Medicine publishes results showing a sharp increase in rates of blood clots in patients implanted with the medical device company's HeartMate II left ventricular assist device.
Thoratec (NSDQ:THOR) shares are under pressure after a New England Journal of Medicine study showing a sharp increase in the rate of thrombosis, or blood clots, in patients implanted with its HeartMate II left ventricular assist device.
Company officials at Thoratec discuss the company's earnings for Q3 2013. Thoratec posted profits of $18.9 million, or 32¢ per share, on sales of $126.4 million for the 3 months ended Sept. 28.
Thoratec shares gain today after the medical device company beats Wall Street's expectations with its 3rd-quarter earnings.
Thoratec (NSDQ:THOR) shares are up today after the medical device company said its 3rd-quarter sales and earnings beat expectations on Wall Street and raised its earnings guidance for the rest of the year.
The Centers for Medicare & Medicaid Services issues new proposed rules for implantable heart pumps, sending Thoratec shares up slightly by prompting investors to rival HeartWare's shares down.
The Centers for Medicare & Medicaid Services issued new proposed rules for left ventricular assist devices, the heart pump implants designed to help patients with end-stage heart disease either make the bridge to transplant or to assist their hearts until the end of life – so-called "destination therapy."
Thoratec shares jump after the medical device company reports Wall Street-beating earnings numbers for the 2nd quarter.
Thoratec (NSDQ:THOR) shares gained 10% this morning after the medical device company reported double-digit sales and earnings results for the 2nd quarter, handily beating Wall Street's expectations.
Thoratec pays $13 million up front to acquire Terumo's DuraHeart II heart pump, with possible milestones down the road worth nearly $44 million.
The FDA approves Thoratec's pocket controller for its HeartMate II implantable heart pump.
Thoratec (NSDQ:THOR) said it got the go-ahead from the FDA to market its HeartMate II pocket controller.
The pocket controller is designed to support the active lifestyles of patients with HeartMate II left ventricular assist devices, the Pleasanton, Calif.-based medical device company stated in a press release.